CIM
BIIB icon

Contravisory Investment Management’s Biogen BIIB Stock Holding History

Contravisory Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.58M Sell
44,329
-348
-0.8% -$66.6K 1.69% 25
2026
Q1 		$8.19M Buy
+44,677
New +$8.23M 1.68% 28
2018
Q1 		– Sell
-21
Closed -$7K – 343
2017
Q4 		$7K Hold
21
– – ﹤0.01% 276
2017
Q3 		$7K Buy
+21
New +$6.22K ﹤0.01% 282

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Contravisory Investment Management's BIIB Position: Q2 2026 in Review

Contravisory Investment Management reduced its Biogen (BIIB) stake by 0.78% in Q2 2026, selling an estimated $66.6K and leaving 44,329 shares worth $9.58M. The position accounts for 1.69% of the portfolio, ranked #25.

Contravisory Investment Management first reported a position in BIIB in Q3 2017 and has held it in 4 quarters since. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Contravisory Investment Management held 44,329 shares of Biogen worth $9.58M as of Q2 2026.
  • Contravisory Investment Management sold 348 Biogen shares in Q2 2026, an estimated $66.6K.
  • Biogen made up 1.69% of Contravisory Investment Management's portfolio in Q2 2026, its #25 holding.
  • Contravisory Investment Management first reported a position in Biogen in Q3 2017 and has held it in 4 quarters since.
  • 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Contravisory Investment Management's 13F filing for Q2 2026, filed 9 Jul 2026.